Breast cancer future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Immunotherapeutic interventions== | ==Immunotherapeutic interventions== | ||
Generally, cancer immunotherapy refers to immune checkpoint inhibitors and cytokines, adoptive cell therapy, and cancer vaccines. | |||
===immune checkpoint inhibitors=== | |||
====Programmed cell death protein 1 (PD-1)==== | |||
Programmed cell death protein 1 (PD-1) is an inhibitory immune checkpoint inhibitor that limits T-cell effector function within tissues, and it is expressed on the surfaces of immune effector cells (T-cells, B cells, NK cells, DCs, and many TILs)and has two known ligands, namely, PD-L1 and PD-L2.<ref name="pmid1396582">Ishida Y, Agata Y, Shibahara K, Honjo T (1992) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=1396582 Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.] ''EMBO J'' 11 (11):3887-95. PMID: [https://pubmed.gov/1396582 1396582]</ref><ref name="pmid12091876">Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al. (2002) [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=12091876 Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.] ''Nat Med'' 8 (8):793-800. [http://dx.doi.org/10.1038/nm730 DOI:10.1038/nm730] PMID: [https://pubmed.gov/12091876 12091876]</ref> | |||
*Anti-PD-1 antibodies (Pembrolizumab, JS001, PDR001, and Nivolumab) | |||
*Anti-PD-L1 antibodies (Atezolizumab and Durvalumab) | |||
==Adoptive cell therapy== | ==Adoptive cell therapy== | ||
===Cancer vaccines=== | ===Cancer vaccines=== | ||
Revision as of 18:55, 26 April 2019
Immunotherapeutic interventions
Generally, cancer immunotherapy refers to immune checkpoint inhibitors and cytokines, adoptive cell therapy, and cancer vaccines.
immune checkpoint inhibitors
Programmed cell death protein 1 (PD-1)
Programmed cell death protein 1 (PD-1) is an inhibitory immune checkpoint inhibitor that limits T-cell effector function within tissues, and it is expressed on the surfaces of immune effector cells (T-cells, B cells, NK cells, DCs, and many TILs)and has two known ligands, namely, PD-L1 and PD-L2.[1][2]
- Anti-PD-1 antibodies (Pembrolizumab, JS001, PDR001, and Nivolumab)
- Anti-PD-L1 antibodies (Atezolizumab and Durvalumab)
Adoptive cell therapy
Cancer vaccines
Personalized medicine and I-SPY 2 clinical trial
- ↑ Ishida Y, Agata Y, Shibahara K, Honjo T (1992) Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11 (11):3887-95. PMID: 1396582
- ↑ Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8 (8):793-800. DOI:10.1038/nm730 PMID: 12091876